The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) could improve outcomes in patients with newly diagnosed mantle-cell lymphoma. METHODS: In this phase 3 trial, we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 (with prednisone administered orally on days 1 to 5) or VR-CAP (R-CHOP regimen, but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11). The primary end point was progression-free survival. RESULTS: After a median follow-up of 40 months, median progression-free survival (according to independent radiologic review) was 14.4 months in the R-CHOP group versus 24.7 months in the VR-CAP group (hazard ratio favoring the VR-CAP group, 0.63; P<0.001), a relative improvement of 59%. On the basis of investigator assessment, the median durations of progression-free survival were 16.1 months and 30.7 months, respectively (hazard ratio, 0.51; P<0.001), a relative improvement of 96%. Secondary end points were consistently improved in the VR-CAP group, including the complete response rate (42% vs. 53%), the median duration of complete response (18.0 months vs. 42.1 months), the median treatment-free interval (20.5 months vs. 40.6 months), and the 4-year overall survival rate (54% vs. 64%). Rates of neutropenia and thrombocytopenia were higher in the VR-CAP group. CONCLUSIONS: VR-CAP was more effective than R-CHOP in patients with newly diagnosed mantle-cell lymphoma but at the cost of increased hematologic toxicity. (Funded by Janssen Research and Development and Millennium Pharmaceuticals; LYM-3002 ClinicalTrials.gov number, NCT00722137.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., et al. (2008) · Blood · doi:10.1182/blood-2007-06-095331 · Cited by 984
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Self-citationDreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., MacDonald, D., Hertzberg, M., Kwan, Y.-L., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 643
Lenz, G., Dreyling, M., Hoster, E., Wörmann, B., Dührsen, U., Metzner, B., Eimermacher, H., Neubauer, A., Wandt, H., Steinhauer, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.133 · Cited by 574
Treatment of Older Patients with Mantle-Cell Lymphoma
Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200920 · Cited by 520
Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma
Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.8435 · Cited by 399
Howard, O. M., Gribben, J. G., Neuberg, D. S., Grossbard, M. L., Poor, C., Janicek, M. J., & Shipp, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1288 · Cited by 372
Lonial, S., Waller, E. K., Richardson, P. G., Jagannath, S., Orlowski, R. Z., Giver, C. R., Jaye, D. L., Francis, D., Giusti, S., Torre, C., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1173 · Cited by 340
Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn656 · Cited by 336
Bortezomib for the Treatment of Mantle Cell Lymphoma
Kane, R. C., Dagher, R., Farrell, A., Ko, C.-W., Sridhara, R., Justice, R., & Pazdur, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0871 · Cited by 332
Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management
Vose, J. M. (2013) · American Journal of Hematology · doi:10.1002/ajh.23615 · Cited by 328
Ruan, J., Martin, P., Furman, R. R., Lee, S. M., Cheung, K., Vose, J. M., LaCasce, A., Morrison, J., Elstrom, R., Ely, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1142 · Cited by 319
Tiemann, M., Schrader, C., Klapper, W., Dreyling, M. H., Campo, E., Norton, A., Berger, F., Kluin, P., Ott, G., Pileri, S., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05716.x · Cited by 315
Determann, O., Hoster, E., Ott, G., Wolfram Bernd, H., Loddenkemper, C., Leo Hansmann, M., Barth, T. E. F., Unterhalt, M., Hiddemann, W., Dreyling, M., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117010 · Cited by 238
Broyl, A., Corthals, S. L., Jongen, J. L., van der Holt, B., Kuiper, R., de Knegt, Y., van Duin, M., el Jarari, L., Bertsch, U., Lokhorst, H. M., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70206-0 · Cited by 219
Hoster, E., Klapper, W., Hermine, O., Kluin-Nelemans, H. C., Walewski, J., van Hoof, A., Trneny, M., Geisler, C. H., Di Raimondo, F., Szymczyk, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.2466 · Cited by 166
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies
Cavaletti, G., & Jakubowiak, A. J. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.483303 · Cited by 155
Dreyling, M. H., Geisler, C., Hermine, O., Kluin‐Nelemans, H. C., Gouill, S. L., Rule, S. A., Shpilberg, O., Walewski, J. A., & Ladetto, M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu264 · Cited by 137
Lonial, S., Richardson, P. G. G., Miguel, J. F. S., Sonneveld, P., Schuster, M. W., Bladé, J., Cavenagh, J. D., Rajkumar, S. V., Jakubowiak, A. J., Esseltine, D.-L. W., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07321.x · Cited by 96
Proteasome function is required for platelet production
Shi, D., Smith, M. C. P., Campbell, R. A., Zimmerman, P. W., Franks, Z. B., Kraemer, B. F., Machlus, K. R., Jing, L., Kamba, P., Schwertz, H., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75247 · Cited by 89
O’Connor, O. A., Moskowitz, C. H., Portlock, C. S., Hamlin, P. A., Straus, D. J., Dumitrescu, O., Sarasohn, D. M. M., Gönen, M., Butos, J. N., Neylon, E., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07466.x · Cited by 82
Guidelines for the investigation and management of mantle cell lymphoma
McKay, P., Leach, M., Jackson, R., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12046 · Cited by 79
Subcutaneous Versus Intravenous Bortezomib
Barbee, M. S., Harvey, R. D., Lonial, S., Kaufman, J. L., Wilson, N. M., McKibbin, T., Hutcherson, D. A., Surati, M. J., Valla, K., & Shah, K. S. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013503122 · Cited by 40
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial
Goy, A. H., Bernstein, S. H., McDonald, A. A., Pickard, M. D., Shi, H., Fleming, M. D., Bryant, B. M., Trepicchio, W. L., Fisher, R. I., Boral, A. L., et al. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.483302 · Cited by 34
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes
Murai, K., Kowata, S., Shimoyama, T., Yashima‐Abo, A., Fujishima, Y., Ito, S., & Ishida, Y. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12342 · Cited by 26
Transplantation for mantle cell lymphoma: is it the right thing to do?
Williams, M. E. (2013) · Hematology · doi:10.1182/asheducation-2013.1.568 · Cited by 14
Cited by
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Self-citationProteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., Szymczyk, M., Bouabdallah, R., Kneba, M., Hallek, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00739-x · Cited by 400
Metadata
- Authors
- Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., Alexeeva, J., Pereira, J., Drach, J., Mayer, J., Hong, X., Okamoto, R., Pei, L., Rooney, B., van de Velde, H., & Cavalli, F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-03-05
- Volume
- 372
- Issue
- 10
- Pages
- 944-953
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158945674
- Cited by
- 386
- References
- 30
- FWCI
- 39.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.